Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingzi Cui

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Frontiers in Pharmacology|September 22, 2025
<i>Stevia rebaudiana</i> Bertoni as a sweet herbal medicine: traditional uses, potential applications, and future developmentLisha Wang, Tianying Chang, Tonggang Zhu, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|April 1, 2026
Molecular mechanisms of shenhong tongluo formula against myocardial ischemia-reperfusion injury: Insights from RNA sequencing, bioinformatics, reverse network pharmacology, molecular docking, and molecular dynamics simulations combined with experimental studiesRong He, Zheng Liang, Jinting Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2022
Molecular basis of differential receptor usage for naturally occurring CD55-binding and -nonbinding coxsackievirus B3 strainsQingling Wang, Qian Yang, Congcong Liu, et al.
Medicine|December 23, 2022
Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysisPeng Xu, Ying Zhang, Tianying Chang, et al.
Emerging Microbes & Infections|July 4, 2020
Profiles of COVID-19 clinical trials in the Chinese Clinical Trial RegistryPeng Xu, Xiangyu Xing, Keying Yu, et al.
Expert Opinion on Investigational Drugs|February 9, 2023
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjectsYanli Wang, Jinling Xue, Zhengjie Su, et al.
Expert Opinion on Biological Therapy|October 5, 2021
A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjectsGuangwen Liu, Zhongnan Xu, Wei Yang, et al.
The Journal of Experimental Medicine|June 5, 2024
Coxsackievirus A10 impairs nail regeneration and induces onychomadesis by mimicking DKK1 to attenuate Wnt signalingYingzi Cui, Qiaoni Shi, Pu Song, et al.
Expert Review of Clinical Pharmacology|March 8, 2023
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trialZhongnan Xu, Zhengzhi Liu, Yanli Wang, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 21, 2024
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjectsZhengzhi Liu, Jinling Xue, Qiaohuan Deng, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Frontiers in Pharmacology|September 22, 2025
<i>Stevia rebaudiana</i> Bertoni as a sweet herbal medicine: traditional uses, potential applications, and future developmentLisha Wang, Tianying Chang, Tonggang Zhu, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|April 1, 2026
Molecular mechanisms of shenhong tongluo formula against myocardial ischemia-reperfusion injury: Insights from RNA sequencing, bioinformatics, reverse network pharmacology, molecular docking, and molecular dynamics simulations combined with experimental studiesRong He, Zheng Liang, Jinting Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2022
Molecular basis of differential receptor usage for naturally occurring CD55-binding and -nonbinding coxsackievirus B3 strainsQingling Wang, Qian Yang, Congcong Liu, et al.
Medicine|December 23, 2022
Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysisPeng Xu, Ying Zhang, Tianying Chang, et al.
Emerging Microbes & Infections|July 4, 2020
Profiles of COVID-19 clinical trials in the Chinese Clinical Trial RegistryPeng Xu, Xiangyu Xing, Keying Yu, et al.
Expert Opinion on Investigational Drugs|February 9, 2023
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjectsYanli Wang, Jinling Xue, Zhengjie Su, et al.
Expert Opinion on Biological Therapy|October 5, 2021
A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjectsGuangwen Liu, Zhongnan Xu, Wei Yang, et al.
The Journal of Experimental Medicine|June 5, 2024
Coxsackievirus A10 impairs nail regeneration and induces onychomadesis by mimicking DKK1 to attenuate Wnt signalingYingzi Cui, Qiaoni Shi, Pu Song, et al.
Expert Review of Clinical Pharmacology|March 8, 2023
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trialZhongnan Xu, Zhengzhi Liu, Yanli Wang, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 21, 2024
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjectsZhengzhi Liu, Jinling Xue, Qiaohuan Deng, et al.
Pageof 6